Advertisement

Search Results for "When Did Amdipharm Start"

07:13 EDT 22nd May 2013 | BioPortfolio

Original Source: Amdipharm acquisition - Comments from Economist Intelligence Unit

Amdipharm is one of the companies that has supposedly found ways to make money out of patent expiry, snapping up drugs that have come off-patent and that research-based pharma companies now see as too low-margin to be worth marketing. In 2011 its UK arm was still loss-making, according to registry filings recorded by Orbis, although its Irish and International arms have been more successful. “Given rising demand for generic products, and the new pro-generic legislation that has been introduced in...

Matching Channels

Paroxysmal supraventricular tachycardia (PSVT)

Paroxysmal supraventricular tachycardia (PSVT) is episodes of rapid heart rate that start in a part of the heart above the ventricles. "Paroxysmal" means from time to time. The heart wil...

Sweden

The Scandinavian country of Sweden is home to a thriving biotechnology industry, one of the top 5 in Europe. Europe has become a global center for the industry, helped by €2 billion worth of fu...

Pubic lice

Pubic lice are small, six-legged creatures that infect the pubic hair area and lay eggs. These lice can also be found in armpit hair and eyebrows. Causes, incidence, and risk factors Pubic lice...

Clinical Trials Phase News

Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will norma...

Germany

Germany is one the top 5 countries in Europe for the biotechnology industry. The €2 billion Innovative Medicines stimulus from the EU has helped, but that is spread over the continent. Over a d...

Matching News

Cinven snaps up Amdipharm for £365 million

Channel Islands-based private equity firm Cinven has reached agreement to acquire UK-based niche generic drugmaker Amdipharm from Vijay and Bhikhu Patel, the Indian billionaires behind Waymade, the gl...

Cinven acquires Amdipharm for $590 million

Cinven is buying Amdipharm for 367 million pounds ($590 million), as part of a plan to create a much larger producer of generic drugs worth as much as 2 billion pounds ($3 billion). The aim is to merg...

Amdipharm and Mercury Pharma merge

As has been expected, Amdipharm and Mercury Pharma - both subsidiaries of Channel Islands-based private equity firm Cinven - have merged to create a single, consolidated, international speciality phar...

Cinven snaps up Amdipharm for £367 million

Channel Islands-based private equity firm Cinven has reached agreement to acquire UK-based niche generic drugmaker Amdipharm from Vijay and Bhikhu Patel, the Indian billionaires behind Waymade, the gl...

Cinven to purchase Amdipharm

Cinven announced today that it is to purchase Amdipharm. Cinven, a private equity group, announced today that it is to buy Amdipharm for 367 million pounds. Amdipharm is a family-owned niche...

Cinven completes acquisition of Amdipharm (News)

31 October 2012: London, UK - European private equity firm, Cinven, today announces completion of its acquisition of Amdipharm, the family-owned international niche pharmaceuticals business, for a ...

CORRECTED-RPT-Cinven buys Amdipharm for 367 mln stg

LONDON, Oct 15 (Reuters) - Private equity group Cinven is buying family-owned niche pharmaceuticals business Amdipharm for 367 million pounds ($590 million) aiming to harness its global client reach....

Amdipharm acquisition - Comments from Economist Intelligence Unit

Amdipharm is one of the companies that has supposedly found ways to make money out of patent expiry, snapping up drugs that have come off-patent and that research-based pharma companies now see as t...

Matching PubMed Articles

Comparison of Grab Start between Elite and Trained Swimmers.

This study analysed motor control during front crawl swimming starts by elite and trained swimmers, based on comparisons of: 1) kinematic and kinetic parameters of the start and 2) variability of thes...

Stop worrying; start growing. Risk research on GM crops is a dead parrot: it is time to start reaping the benefits of GM.

Chelating or bridging Pd(ii) and Pt(ii) metalloligands from the functional phosphine ligand N-(diphenylphosphino)-1,3,4-thiadiazol-2-amine. New heterometallic Pd(ii)/Pt(ii) and Pt(ii)/Au(i) complexes.

The reaction of two equivalents of the functional phosphine ligand N-(diphenylphosphino)-1,3,4-thiadiazol-2-amine Ph(2)PNHC[upper bond 1 start][double bond, length as m-dash]NNCHS[upper bond 1 end] (2...

Genome-wide identification and divergent transcriptional expression of StAR-related lipid transfer (START) genes in teleosts.

The lipid transfer reactions and the steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) genes have a major role in lipid metabolism. However, START genes and their physiologi...

The categorisation of swimming start performance with reference to force generation on the main block and footrest components of the Omega OSB11 start blocks.

Abstract Work presented in this paper provides a methodology for categorising swimming start performance based on peak force production on the main block and footrest components of the Omega OSB11 sta...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement